Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Carisma Therapeutics Inc CARM

Healthcare Biotechnology
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the... see more

Recent & Breaking News (NDAQ:CARM)

Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide Business Update Highlighting Regulatory Progress and Commercial Opportunity for Vicinium®

Business Wire February 25, 2020

Sesen Bio Announces Changes to the Board of Directors as the Company Advances Toward Commercialization of Vicinium®

Business Wire February 24, 2020

Sesen Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 31, 2020

Sesen Bio Completes Successful CMC Type B pre-BLA Meeting with FDA

Business Wire December 4, 2019

Sesen Bio Reports Third Quarter 2019 Financial Results and Update on Regulatory Activities Related to Vicinium

Business Wire November 12, 2019

Sesen Bio Announces Successful Type C Meeting with FDA for Vicinium

Business Wire November 5, 2019

Sesen Bio Strengthens Strategic and Financial Optionality

Business Wire October 29, 2019

Sesen Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Business Wire September 3, 2019

Sesen Bio Announces CFO Transition as Company Drives Towards Anticipated Initiation of BLA Submission in 4Q 2019

Business Wire August 26, 2019

Sesen Bio Reports Positive, Preliminary Data Update from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer

Business Wire August 8, 2019

Sesen Bio Strengthens Leadership Team

Business Wire August 5, 2019

Sesen Bio to Present at the Canaccord Genuity 39th Annual Growth Conference

Business Wire July 31, 2019

Sesen Bio Announces Retirement of Leslie L. Dan

Business Wire July 17, 2019

Sesen Bio Announces Pricing of Public Offering of Common Stock and Warrants

Business Wire June 19, 2019

Sesen Bio Announces Proposed Public Offering of Common Stock and Warrants

Business Wire June 18, 2019

Sesen Bio Announces Successful Pre-BLA Meeting with FDA for Vicinium®

Business Wire June 10, 2019

Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide Regulatory Update on Pre-BLA Meeting for Vicinium®

Business Wire June 7, 2019

Sesen Bio Reports First Quarter 2019 Financial Results and Updated, Preliminary Primary and Additional Secondary Endpoint Data from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer

Business Wire May 13, 2019

Will the Good News for Vicinium Continue for Sesen Bio, They Will Tell Investors Soon

Press Releases May 1, 2019

Sesen Bio to Host Conference Call to Review First Quarter 2019 Financial Results and Updated Preliminary Data from Phase 3 VISTA Trial

Business Wire April 29, 2019